NGM Bio Presents Updated Preliminary Findings for a Subgroup of Patients with Advanced Prostate Cancer from the Ongoing Phase 1a Dose Escalation Trial of NGM120 in Patients with Advanced Solid Tumors at the ESMO Annual Congress
September 06 2022 - 8:00AM
NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a
biotechnology company focused on discovering and developing
transformative therapeutics for patients, today announced that
updated preliminary findings from its open-label Phase 1a dose
escalation study of NGM120, a novel GFRAL antagonist antibody drug
candidate, in a subset of patients with advanced prostate cancer
will be presented at the European Society for Medical Oncology
(ESMO) Annual Congress on Sunday, September 11, 2022. These results
demonstrate that treatment with NGM120 was well tolerated to date
in the study with no dose-limiting toxicities and provide
encouraging signals of anti-cancer activity in patients with
advanced prostate cancer.
The poster titled “Initial Results of a Cohort of Advanced
Prostate Cancer Patients in a Phase 1a Study of NGM120, a
First-in-class Anti-GDNF Family Receptor Alpha Like (GFRAL)
Antibody” (publication number: 1402P) is available to conference
attendees for the duration of the ESMO Annual Congress and will be
archived on the ‘Presentations and Publications’ page of NGM Bio’s
website here.
“We are pleased to share these updated findings from the Phase
1a dose escalation trial of NGM120,” said Alex DePaoli, M.D.,
Senior Vice President, Chief Translational Officer at NGM Bio.
“While still preliminary, these findings provide an interesting
signal that encourages further study of NGM120 for the treatment of
patients with advanced prostate cancer.”
The poster’s first author, Igor Medic, M.D., Cancer Center
Oncology Medical Group, Sharp Grossmont Hospital, commented, “While
a small sample size, the durable response and reduction of PSA to
undetectable levels seen in this study in a patient with prostate
cancer refractory to multiple lines of treatment is intriguing. I
look forward to further clinical study of NGM120.”
NGM120 is an antagonist antibody that binds glial cell-derived
neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth
differentiation factor 15 (GDF15) signaling. NGM Bio scientists
have made several important discoveries related to GDF15, including
identification of its cognate receptor, GFRAL. Evidence has shown
that serum levels of GDF15 are elevated in patients with several
tumor types, including non-small cell lung cancer, melanoma,
pancreatic, prostate, colorectal, gastric, esophageal and ovarian
cancer, and are associated with a worse prognosis in multiple
cancers. For more details on NGM Bio’s oncology portfolio visit NGM
Bio’s website at
https://www.ngmbio.com/discovery-engine/oncology/.
In addition to the Phase 1a trial testing NGM120 as a
monotherapy for the treatment of patients with solid tumors and the
recently initiated Phase 1b trial testing NGM120 in combination
with one or more lines of hormone therapies in patients with mCRPC,
NGM Bio is conducting a Phase 1b dose escalation trial of NGM120 in
combination with gemcitabine and Nab-paclitaxel in patients with
metastatic pancreatic cancer and a Phase 2 randomized, single-blind
(investigator-blinded), placebo-controlled, multi-center expansion
trial of NGM120 in combination with gemcitabine and Nab-paclitaxel
as a first-line treatment in patients with metastatic pancreatic
cancer (referred to as the PINNACLES trial).
About NGM Bio
NGM Bio is focused on discovering and developing novel,
life-changing medicines for people whose health and lives have been
disrupted by disease. The company’s biology-centric drug discovery
approach aims to seamlessly integrate interrogation of complex
disease-associated biology and protein engineering expertise to
unlock proprietary insights that are leveraged to generate
promising product candidates and enable their rapid advancement
into proof-of-concept studies. As explorers on the frontier of
life-changing science, NGM Bio aspires to operate one of the most
productive research and development engines in the
biopharmaceutical industry. All therapeutic candidates in the NGM
Bio pipeline have been generated by its in-house discovery engine,
always led by biology and motivated by unmet patient need. Today,
the company has seven programs in clinical
development, including four in Phase 2 or 2b
studies, across three therapeutic areas:
cancer, retinal diseases and liver and
metabolic diseases. Visit us at www.ngmbio.com for more
information.
Forward-Looking Statements Statements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
“will,” “look forward,” “potential,” “promising,” “preliminary,”
“encouraging,” “goal,” “aspires,” “aims” and similar expressions
(as well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. These statements include those related
to: NGM Bio’s product candidates, including the potential of NGM
Bio’s oncology product candidate, NGM120 to treat cancer; potential
outcomes suggested by preliminary findings regarding NGM120; NGM
Bio’s aspiration to operate one of the most productive research and
development engines in the biopharmaceutical industry and other
statements that are not historical fact. Because such statements
deal with future events and are based on NGM Bio’s current
expectations, they are subject to various risks and uncertainties,
and actual results, performance or achievements of NGM Bio could
differ materially from those described in or implied by the
statements in this press release. These forward-looking statements
are subject to risks and uncertainties, including, without
limitation, risks and uncertainties associated with the costly and
time-consuming pharmaceutical product development process and the
uncertainty of clinical success, including risks related to failure
or delays in successfully initiating, enrolling, reporting data
from or completing clinical studies, as well as the risks that
results obtained in preclinical or clinical trials to date may not
be indicative of results obtained in ongoing or future trials, that
preliminary results will differ from final results and that NGM
Bio’s product candidates may otherwise not be tolerable and
effective treatments in their planned indications; the ongoing
COVID-19 pandemic, which has adversely affected, and could
materially and adversely affect in the future, NGM Bio’s business
and operations, including NGM Bio’s ability to timely supply,
initiate, enroll and complete its ongoing and future clinical
trials; the time-consuming and uncertain regulatory approval
process; NGM Bio’s reliance on third-party manufacturers for its
product candidates and the risks inherent in manufacturing and
testing pharmaceutical products; the sufficiency of NGM Bio’s cash
resources, including to fund its wholly-owned programs, and NGM
Bio’s need for additional capital; and other risks and
uncertainties affecting NGM Bio and its development programs,
including those discussed in the section titled “Risk Factors” in
NGM Bio’s annual report on Form 10-Q for the quarter ended June 30,
2022 filed with the United States Securities and Exchange
Commission (SEC) on August 4, 2022 and future filings and reports
that NGM Bio makes from time to time with the SEC. Except as
required by law, NGM Bio assumes no obligation to update these
forward-looking statements, or to update the reasons if actual
results differ materially from those anticipated in the
forward-looking statements.
Investor
Contact:Brian Schoelkopfir@ngmbio.com |
Media
Contact:media@ngmbio.com |
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Jul 2024 to Aug 2024
NGM Biopharmaceuticals (NASDAQ:NGM)
Historical Stock Chart
From Aug 2023 to Aug 2024